Dr. Lin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
800 Ridgeview Drive
Horsham, PA 19044
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1997 - 2000- Brigham and Women's HospitalResidency, Internal Medicine, 1995 - 1997
Yale School of MedicineClass of 1995
Certifications & Licensure
PA State Medical License 2011 - 2024- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients Start of enrollment: 2004 Mar 01
- Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Feb 01
Publications & Presentations
PubMed
- 304 citationsFlavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocyt...John C. Byrd, Thomas S. Lin, James T. Dalton, Di Wu, Mitch A. Phelps
Blood. 2007-01-15 - 65 citationsManagement guidelines for the use of alemtuzumab in chronic lymphocytic leukemiaAnders Österborg, Robert Foa, R. F. Bezares, Claire Dearden, Martin J. S. Dyer
Leukemia. 2009-07-23 - 4 citationsPhase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.Robert A Baiocchi, Lapo Alinari, Mark E Lustberg, Thomas S Lin, Pierluigi Porcu
Cancer. 2011-06-01
Abstracts/Posters
- Daratumumab (DARA) Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma (NDMM) after Frontline Autolo...Thomas S. Lin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Daratumumab (DARA) Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma (NDMM) after Frontline Autolo...Thomas S. Lin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
